Back to Search
Start Over
[Innovative therapeutic drug combination for type 2 diabetes at cardiorenal risk].
- Source :
-
Revue medicale suisse [Rev Med Suisse] 2024 Aug 28; Vol. 20 (884), pp. 1492-1497. - Publication Year :
- 2024
-
Abstract
- Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiorenal -prognosis of at-risk patients with type 2 diabetes thanks to pleiotropic effects that are either common or specific. This article discusses the clinical efficacy of a combined therapy with the two medications. Data were obtained from post hoc analyses of subgroups of participants to cardiovascular outcome trials and from real-life observational retro-spective cohort studies. The reported superiority of the combination versus either monotherapy should be confirmed in an ongoing large prospective trial (PRECIDENTD). The extra-cost of such a combined therapy as well as the common underuse of each pharmacological class in daily clinical practice deserve attention.<br />Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Subjects :
- Humans
Cardiovascular Diseases prevention & control
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 complications
Sodium-Glucose Transporter 2 Inhibitors administration & dosage
Sodium-Glucose Transporter 2 Inhibitors therapeutic use
Glucagon-Like Peptide-1 Receptor agonists
Drug Therapy, Combination methods
Hypoglycemic Agents administration & dosage
Hypoglycemic Agents therapeutic use
Subjects
Details
- Language :
- French
- ISSN :
- 1660-9379
- Volume :
- 20
- Issue :
- 884
- Database :
- MEDLINE
- Journal :
- Revue medicale suisse
- Publication Type :
- Academic Journal
- Accession number :
- 39219392
- Full Text :
- https://doi.org/10.53738/REVMED.2024.20.884.1492